Trials / Completed
CompletedNCT05225324
A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)
Equfina Tablet 50 mg Post Marketing Surveillance Protocol
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 702 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the following in relation to the safety of Equfina Tablet 50 mg in the post marketing setting: 1. Serious adverse events (SAEs) and adverse drug reactions (ADRs) 2. Unexpected adverse events (AEs) and ADRs not reflected in the precautions for use 3. Known ADRs 4. Non-serious ADRs 5. Other safety and efficacy related information.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Equfina 50 mg | Equfina 50 mg tablets. |
Timeline
- Start date
- 2021-06-03
- Primary completion
- 2025-03-20
- Completion
- 2025-03-20
- First posted
- 2022-02-04
- Last updated
- 2025-06-22
Locations
27 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05225324. Inclusion in this directory is not an endorsement.